Research suggests outsourcing and the increasing incidence of adverse drug reactions (ADR) will be primary drivers of growth in the global pharmacovigilance market.
In China, people often equate PV with adverse drug reaction (ADR) monitoring, but in fact, PV is not simply ADR monitoring; it is a gradual outward expanding process with ADR monitoring at its core.